Skip navigation

Niven R. Narain, Ph.D.

Dr. Niven R. Narain is Co-founder, President & CEO of BERG, LLC, a Boston-based biopharma driving next-generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He has been recognized as a pioneer in technology development at the intersection of Biology and AI, and is the inventor of the Interrogative Biology® platform that has unraveled actionable disease insight leading to both de novo and repurposed development. He has overseen development of deep pipeline in oncology, metabolic, rare, and CNS diseases, namely BPM 31510 currently in Phase 2 trials for cancer, covered by over 550 issued and pending US and international patents.

Boston Business Journal top 40 leaders under 40

Narain is a member of the NASA/Gene Lab Steering Committee, Advisor to DoD leadership on breast and prostate cancer, and has forged strategic partnerships with industry, academia, and US and UK governments. He is an industry thought leader in precision medicine, drug development, and AI/ML, serving as a frequent speaker at Economist, Bloomberg, Financial Times, Wired, and Aspen Ideas meetings in addition to many international meetings on medicine and technology. Dr. Narain has been featured on CNN, BBC, CNBC, Fox Business, Fortune, and the Wall Street Journal, among others. He is a recipient of the UM/Sylvester Cancer Center’s Zubrod Prize and an NIH/NIDDK Award of Excellence. Dr. Narain was named to the Boston Business Journal’s40 Under 40” list (2014), was an EY Entrepreneur of The-Year finalist (2018), and was selected for Deep Knowledge Analytics’ Top 100 AI Pioneers in Drug Discovery and Advanced Healthcare list (2019).

featured on CNN, BBC, CNBC, Forbes, Fox Business, and the Wall Street Journal.

Narain obtained a BS in Biological Sciences from St. John’s University, NY and a Ph.D. in Biochemistry with focus on Cancer Biology at the University of Miami Miller School of Medicine where he also did clinical research training in Dermatology and Cutaneous Surgery, serving as Director of Cutaneous Oncology Research. His research has been published in Nature Medicine and Cell Metabolism with international collaborators from academia, NIH, and DoD. Narain remains active in community leadership/mentoring programs such as Science from Scientists Intel, Upward Bound, and HHMI programs, serves as a St. John’s and University of Miami Boston Chapter alumni advisor, and is an active member of the Trinity Church Boston.

Dr. Narain is most passionate about improving patient care and enabling increased access to innovative medicines towards improved healthcare outcomes.